Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-25-033143
Filing Date
2025-04-18
Accepted
2025-04-18 08:03:03
Documents
1
Period of Report
2025-04-16

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT ownership.html 4  
1 OWNERSHIP DOCUMENT ownership.xml 4 4268
  Complete submission text file 0001213900-25-033143.txt   5754
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Issuer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 GREENHILL ROAD EASTWOOD C3 SA 5063
Business Address
Davies Peter Miles Winston (Reporting) CIK: 0002030200 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41157 | Film No.: 25849249